SEARCH RESULTS

6 RESULTS

Marsel Mesulam on Aducanumab Approval Sparks Backlash

COMMENT After 18 dry years, the hunger for a novel Alzheimer’s drug had reached a fever pitch. Everyone was primed to welcome a new addition with loud cheers. This has clearly not been the response elicited by the FDA’s approval of aducanumab (Aduhelm). To ...

Marsel Mesulam on Forget Typical Alzheimer's: AI Finds Four Types.

COMMENT The fact that Alzheimer’s disease (AD) is heterogeneous and that the Braak staging of neurofibrillary tauopathy can be violated has been known for nearly 30 years through work on posterior cortical atrophy and primary progressive aphasia (PPA) (Mesulam, ...

Current Filters

  • TYPE: Comment x
  • Commentator: Mesulam, Marsel x

Remove all filters

Filter By

DATE RANGE
  • All
  • Past 7 Days
  • Past 30 Days
  • Past 90 Days
  • Past 12 Months
  • Specific Dates
    1. From
      To

TYPE